SecProbe.io

Mail Stop 4546
        April  19, 2017

Tim Van Hauwermeiren
Chief Executive Officer
argenx N.V.
Willemstraat 5
4811 AH, Breda, the Netherlands

Re: argenx N.V.
Amendment No. 1 to
Draft Registration Statement on Form F -1
Submitted April  5, 2017
  CIK No. 0001697862

Dear Mr. Van Hauwermeiren :

We have reviewed your amended draft registration statement  and have the following
comments.  In some of our comments, we may ask you to provide us with information so we
may better understand your disclosure.

Please respond to this letter by providing the requested information and either submitting
an amended draft registration statement or publicly filing your registration statement on
EDGAR.  If you do not believe our comments apply to your facts and circumstances or do not
believe an amendment is appropriate, please tell us why in your response.

After reviewing the information you provide in response to these  comments  and your
amende d draft registration statement or filed registration statement,  we may have  additional
comments.

Overview of Our Anticipated Restructuring and Redomiciliation, page 161

1. We note your plans to redomicile from the Netherlands to Belgium following completi on
of the offering.  Please tell us whether you intend to register the offer of securities in the
redomiciliation under the Securities Act of 1933.  If you do not intend to register the
transaction, please tell us the exemption(s) from registration upon wh ich you intend to
rely, including the facts supporting your reliance on such exemption(s).  Please also
provide us with your analysis as to whether the tender offer rules will apply to this
transaction.

Tim Van Hauwermeiren
Argenx N.V.
April  19, 2017
Page 2

2. We note that your purpose for the redomiciliation i s that value creation is not properly
aligned with your intellectual property ownership structures as required under the Base
Erosion and Profit Shifting project of the Organization for Economic Co -operation and
Development, and that you face a compliance burden as a company existing under Dutch
law with shares listed on Euronext Brussels.  Please disclose the potential risks or costs to
the company that may occur if you are unable to complete the redomiciliation .

Phase 1 Part of Phase 1/2 Clinical Trial  in Patients with Advanced Malignancies Expressing
CD70, page 122

3. We note your  response to our prior comment 13 .  Please disclose the definitions used for
Grade 3 and Grade 4 drug -related adverse events.

Collaborations, page 132
License Agreements, pag e 136

4. We note your discussion in these sections of several colla boration and license
agreements .  However, you have only filed the patent license agreement with The Board
of Regents of the University of Texas System as an exhibit.  Please file these agreements
as exhibits to the registration statement or tell us why you believe that you are not
required to file such agreements pursuant to Item 601(b)(10) of Regulation S -K.

Description of Share Capital, page 189
Preemptive Rights, page 190

5. We note your disclosure that the shareholders at the General Meeting on April 26, 2017
will be asked to designate the board of directors to issue additional shares and grant rights
to subscribe for shares and to limit or exclud e preemption rights of shareholders for such
shares for a period starting on April 26, 2017 and ending on December 31, 2017 and for a
period of 18 months from the day of the meeting.  We also note that the first
authorization is for the purpose of admissio n to listing and trading of the new ordinary
shares on NASDAQ while the second authorization can also be used for such purpose.
Please disclose the main purpose  for the limitation or exclusion of the preemptive rights
for the second authorization for  18 m onths and whether such limitation or exclusion is
intended to benefit specific persons.   Refer to Form 9.A.3 of Form 20 -F.

Tim Van Hauwermeiren
Argenx N.V.
April  19, 2017
Page 3

 You may contact Sasha Parikh  at (202) 551 -3627 or Kevin Vaughn, Accounting Branch
Chief,  at (202) 551 -3494 if you have questio ns regarding comments on the financial statements
and related matters.  Please contact Ada D. Sarmento  at (202) 551 -3798 or Erin Jaskot, Special
Counsel,  at (202) 551 -3442 with any other questions.

Sincerely,

 /s/ Erin K. Jaskot, for

Suzanne Hayes
Assistant Director
Offic e of Healthcare and Insurance

cc:  Edwin O’Connor
 Goodwin Procter LLP